三友医疗：与韩国细基生物签署战略合作和经销协议

Core Viewpoint - The company has signed a strategic cooperation and distribution agreement with a South Korean firm, obtaining exclusive and non-transferable distribution rights for Novosis products in mainland China, which will enhance its product line in the orthopedic biomaterials sector [1] Group 1: Agreement Details - The agreement was signed on December 2, 2025, with a validity period of six years from the date the product receives medical device registration from the Chinese regulatory authority [1] - Novosis is a recombinant human bone morphogenetic protein BMP-2 biomaterial product that promotes new bone formation [1] Group 2: Impact on Company - This collaboration will enrich the company's product offerings and improve its positioning in the orthopedic biomaterials market [1] - However, there is uncertainty regarding the product's registration approval and market launch, making it difficult to predict the specific impact on the company's performance [1]